Vijeta Kumari

Vijeta Kumari

Auto-generated profile, based on publicly available information

Vijeta Kumari

Laboratory of Natural Product Chemistry, Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS Pilani), Pilani Campus, Pilani – 333031, Rajasthan, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
PAPrashant S. Auti
Prashant S. Auti
Arijit NandiArijit Nandi
Arijit Nandi
VKVijeta Kumari
Vijeta Kumari
APAtish T. Paul
Atish T. Paul
A novel series of indolyl oxoacetamide-quinazolinone hybrid analogues (9aa–9df) were designed, synthesized, and evaluated for their in vitro pancreatic lipase (PL) inhibitory potential that may lead to efficient anti-obesity agents.

1 December 2025
Verified
Book Chapter
Closed access
PDF file
ASAmit Sharma
Amit Sharma
VKVijeta Kumari
Vijeta Kumari
RKRipunjay Kalita
Ripunjay Kalita
HJHemant R. Jadhav
Hemant R. Jadhav
ABAmritansh Bhanot
Amritansh Bhanot
Caspases, a group of cysteine proteases, play a key role in regulating apoptosis. Proteins in this family facilitate the proteolytic degradation of multiple cellular components. Beyond apoptosis, caspases play a significant role in a variety of molecular processes. As crucial components of several cellular pathways, their improper activation or deactivation can have serious consequences and contribute to various disease conditions. Likewise, abnormal activation of caspases is among the factors contributing to neuropathologies linked to Alzheimer's disease (AD), a type of dementia that significantly impairs neuropsychiatric and cognitive functions. Since caspase activation in AD might be an early event linked directly to neurodegeneration, caspases represent promising therapeutic targets for treating this condition. Recent studies are shedding light on the mechanisms by which caspases contribute to the progression of AD. This chapter will examine studies that detail the role of caspases in the AD brain and focus on the in-depth properties and characteristics of caspase inhibitors identified so far, along with their therapeutic potential in animal and clinical studies. Additionally, a brief overview of the achievements and current challenges is provided, offering further perspectives for the continued development of effective caspase inhibitors for AD. <!----> <!----> <!----> <!---->